No Data
Unpacking the Latest Options Trading Trends in Cisco Systems
Cisco: Architecting Sustainability in Storage Area Networks
Cisco: Cleaner Air, Healthier Buildings: How Carbon Reform Is Modernizing Indoor Environments for Health and Efficiency
Salesforce Earnings Cap a Banner Quarter for Software Stocks
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Haisco Pharmaceutical Group (002653.SZ): has obtained the "Notice of Drug Clinical Trial Approval" for the innovative drug HSK46575 tablets.
On December 4th, Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Tibet Haisco Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The tablet is named HSK46575 Tablet and is intended for the treatment of prostate cancer. HSK46575 Tablet is a self-developed oral, potent, and highly selective small molecule inhibitor designed for the treatment of prostate cancer. Preclinical research results indicate that this product has a clear target, precise efficacy, and good safety profile, making it a highly promising small molecule drug with significant potential for development. The benefits/risks of clinical application.
